<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285271</url>
  </required_header>
  <id_info>
    <org_study_id>10-017</org_study_id>
    <secondary_id>2010-023942-63</secondary_id>
    <nct_id>NCT01285271</nct_id>
  </id_info>
  <brief_title>A Pre- and Post- Coronary Artery Bypass Graft Implantation Disposed Application of Xenon</brief_title>
  <acronym>CArDiAX</acronym>
  <official_title>The Safety and Feasibility of Delivering Xenon to Patients Before and After Coronary Artery Bypass Graft Implantation: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether xenon - as compared to sevoflurane - can be&#xD;
      applied safely in patients for general anesthesia before and after CABG implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted by two investigator types: The study enrollment and the&#xD;
      post-anesthesia follow-up will be performed by Investigator I who is blinded to the study&#xD;
      treatment. Investigator II will only perform general anaesthesia for CABG surgery and will&#xD;
      therefore necessarily be unblinded to the treatment conditions.&#xD;
&#xD;
      Patients will be randomly assigned to one of the following study groups. Group 1 (Xenon) will&#xD;
      receive xenon for maintenance of balanced anesthesia for CABG surgery before and after&#xD;
      extracorporal circulation. Group 2 (Sevoflurane) will receive sevoflurane for maintenance of&#xD;
      balanced anesthesia for CABG surgery before and after extracorporal circulation. During&#xD;
      extracorporal circulation, general anesthesia will be maintained intravenously in both&#xD;
      groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the safety and feasibility of xenon application for general anesthesia before and after CABG implantation</measure>
    <time_frame>an average of 4 to 6 hours</time_frame>
    <description>The feasibility of xenon application compared to sevoflurane application will be assessed by:&#xD;
The depth of anaesthesia level&#xD;
The peri-anaesthetic respiratory profile&#xD;
The peri-anaesthetic haemodynamic profile&#xD;
The following safety parameters will be assessed:&#xD;
Doses and concentration of study treatments&#xD;
Trans-esophageal echocardiography&#xD;
Measures of renal function&#xD;
Intra-operative blood loss and amount of transfused blood/products&#xD;
Need for hemodynamic and inotropic support&#xD;
The patient's regional cerebral tissue oxygenation rSO2&#xD;
The incidence of AE and SAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy and safety criteria</measure>
    <time_frame>6 days</time_frame>
    <description>The following secondary efficacy parameters will be assessed:&#xD;
the patients organ function status&#xD;
The severity of postoperative critical illness&#xD;
The incidence of Post-operative Delirium (POD)&#xD;
The duration of postoperative intensive care unit and in-hospital stay&#xD;
Secondary safety parameters:&#xD;
hemodynamic and respiratory profile, including vital signs&#xD;
incidence of major adverse cardiac and cerebral events (MACCE)&#xD;
laboratory parameters -post-operative pain&#xD;
further AE and SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality and contentment questioning</measure>
    <time_frame>1 year</time_frame>
    <description>Patients will be contacted by telephone one year after surgery for a one year mortality and contentment examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Xenon</condition>
  <condition>Sevoflurane</condition>
  <condition>Anesthetics, Inhalation</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Bypass</condition>
  <arm_group>
    <arm_group_label>Xenon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xenon will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevoflurane will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenon</intervention_name>
    <description>gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation</description>
    <arm_group_label>Xenon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation</description>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with coronary artery disease scheduled for elective CABG&#xD;
&#xD;
          -  Patients willing and able to complete the requirements of this study&#xD;
&#xD;
          -  Ejection Fraction &gt; 50%&#xD;
&#xD;
          -  EuroSCORE â‰¤ 8&#xD;
&#xD;
          -  men and women &gt;= 50 yrs&#xD;
&#xD;
          -  women without childbearing potential&#xD;
&#xD;
          -  ASA Score II-IV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of informed consent&#xD;
&#xD;
          -  EuroSCORE &lt; 8&#xD;
&#xD;
          -  MMSE &lt; 24&#xD;
&#xD;
          -  Age &lt; 50 years&#xD;
&#xD;
          -  COPD GOLD &gt; II, increased need of oxygen&#xD;
&#xD;
          -  Renal dysfunction&#xD;
&#xD;
          -  Liver function disorders&#xD;
&#xD;
          -  Acute coronary syndrome during the last 24 hours; hemodynamic instability&#xD;
&#xD;
          -  Requirement of inotropic support&#xD;
&#xD;
          -  Off-pump-surgery&#xD;
&#xD;
          -  Disabling neuropsychiatric disorders&#xD;
&#xD;
          -  History of stroke with residuals&#xD;
&#xD;
          -  Hypersensitivity to the study anaesthetics&#xD;
&#xD;
          -  Increased intracranial pressure&#xD;
&#xD;
          -  Pregnancy and lactation period&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Presumed uncooperativeness or legal incapacity&#xD;
&#xD;
          -  Participation in a concomitant trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Coburn, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, University Hospital Aachen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology, University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>xenon</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>cardiac anesthesia</keyword>
  <keyword>CABG</keyword>
  <keyword>Bypass surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

